cardiac med
HF Դ ŸĿ(link)
CCB(link)
50kg ( 500 ͽ) : 1mcg/kg/min =3mg/hr 500/뷮mg x 3 cc/hr= (ְ mcg) x 1500/뷮 mds
1000 ͽ : (ְ mcg) x 3000/ 뷮 mds
: ۿ
concor, atacand post MI , HF ȯڿ molsiton d/c
Ÿ ( Ȯ ȿ ) : Ȯȿ ϰ л(л Ĺκ ϴ, ٰ µ), tachycardia ȿ´
l 250mg(1A)
, 500cc ͽ , 20cc/hr 50kgȯڿ
ָ -> 3.3ug / kg/ min
l Ÿ 뷮 ( 3-15 ug/kg/min)
l 200 ug/kg/min ϰ ɼ ִ(ȯ ġ)
l ȯ
l ִ 2A 500mix 40cc/hr(15ug/kg/min) ִġ
b1 ۿ , ̾ b2ۿ(Ȯ) 뷮 ɹⷮ, ɹڵ ϰų (CO reflex bradycardia) CO , SVRҷ MAP , ۿ: VPC, tachycardia (ȯ ġ)
½ɽ 游 =PCWP
(ȯ ġ)= δ()
refractory heart
failure , cardiogenic shock (ȯ ġ)
Ÿο ڱ ۾ Ű, ɱ ҼҸ
Ų. ɺ ̹ ۾ 䱸 ִȭ Ǿ־ ɺȯڿ طο
ִ.(ȯ ġ)
=> õõ Ѿ heart failure ް ִ ȯڰ dz ִ.(¥ PO )()
Vassopressor °? SBP base 30mmHg, MAP< 60϶
chronotrope, inotroph coronary vasodilation Ų. inotrope effect myocardial oxygen demend vasodilation ä . daily inotrophԴ occult ischemia ־ daily electrocardiogram screening ʿ ִ.(uptodate)
Excessive vasoconstriction ø , extremeties inadequate perfusion ų ִ. CO ʰ, volume ¿ SVR 1300dynes x sec/cm5 Ҽ ִ.(uptodate)
ۿ : Cardiovascular: Increased heart rate, increased blood pressure, increased ventricular ectopic activity, hypotension, premature ventricular beats (5%, dose related), anginal pain (1% to 3%), nonspecific chest pain (1% to 3%), palpitation (1% to 3%)(uptodate19.3 dobutamine)
-> ɰѰ δ.()
Ĺ ɽǼຸٴ ø(Ÿ ϴ) , tachycardia ü ִ. , ڴٷ (1A
500cc ͽؼ 20mds start)
l 400mg(1A) 500cc ͽ , 20cc/hr 50kg ȯ -> 5.3ug / kg/ min ̿뷮 2 ̻ ٰ
l Ĺ 1~2ug/kg/min : ַ D1 receptor : renal, mesenteric, cerebral, coronary ۿϿ (uptodate)
2~5ug/kg/min : b1 STROKE VOL ణ, b2 Ȯ ణ , a1 SVR : net effect : ణ л(uptodate)
5-10ug/kg/min : b1 receptor ۿ(ַ STROKE VOL, VARIABLE HR) (uptodate)
>10ug/kg/min : ַ a receptor ȿ (uptodate)
20ug/kg/min Ѿ л¿ ̵ .(uptodate 19.3 dopamine)
20~30ug/kg/min̻ direct vasodilator(epinephrine, norepinephrine) غƶ(uptodate 19.3 dopamine)
l
ۿ (uptodate
19.3 dopamine)
Freqeunt
Cardiovascular: Ectopic beats, tachycardia, anginal pain, palpitation, hypotension, vasoconstriction (uptodate 19.3 dopamine)
Headache , Nausea and vomiting , Dyspnea (uptodate 19.3 dopamine)
Infrequent:
Cardiovascular: Aberrant conduction, bradycardia, widened QRS complex, ventricular arrhythmia (high dose), gangrene (high dose), hypertension (uptodate 19.3 dopamine)
Anxiety , Piloerection, serum glucose increased (usually not above normal limits) ,Ⱦл, Ȯ. Azotemia, polyuria(uptodate 19.3 dopamine)
Esmolol(극 100mg)
(AF
RVR) : ó 25mg (1а) -> ٷ ̾ 10mg 4а -> ȿ
-> 25mg 1а -> 20mg 4а -> ȿ -> 25mg 1а -> 30mg 4а -> 25mg 1а -> 40mg 4а(ִ
60mg )
ƹ̿ٷ150mg/1A
ȭ: 5mg/kg ֻ 250ml Ͽ 20-2ð
60kg
2A
250cc ͽϿ 125cc/hr -
750cc/hr ӵ
24ð
2-3ȸ ݺ .
: 10-20mg/kg ֻ 250ml Ͽ 2-3ϰ. 1 600-800mg, 1 ִ 1200mg. ֻ 1°, 汸(1 600mg) ġȯŰ 1
800-1000mg
4A(600mg)-8A(1200mg) 250cc mix Ͽ 5cc/hr(2) -
3.3cc/hr(3)
鼭
뷮 ¿ 汸 ġȯ (ڴٷ 200mg 1T tid)
ȯ ġ : ʱ 300mg IV (̰ ) ι° 150mg IV : ɽǼ , 浿 ɽǺƿ
ȴ, а Ҽ ִ(ȯ ġ)
븣dz(septic shock ַ, cardiogenic
shock ¾) 븣Ƶ巹 0.1% 10ml( norepinephrine bitartrate 20/10)
a1
vasoconstriction > b1 chronotrophic
effect a1
vasoconstriction reflex bradycardia HR ״ Ȥ , CO
, SVR(uptodate) MAP
ҽŰ, septic shock ҳ ջ߾Ѵ(ȯ ġ)
-
- ʱ 8-12 mcg/min ֻ,
, 뷮 2-4 mcg/min ֻ, 68 mg/day //⼭ 뷮 дkg ƴ϶ д// ( 20mg 500 ͽϸ 40ug/mL
)
- ʱ 0.5-1 mcg/min ֻ, ġ ʴ ũ ȯڴ 8-30 mcg/min
septic shock ġ뷮
0.2~1.3ug/kg/min : 5%500 2A(40mg) mixϸ 1mcg/min ַϸ 37.5mds(ȯ ġ)
ACLS dosing range : 0.1-0.5 mcg/kg/minute
(6-30 mcg/minute in a 60 kg patient)(uptodate19.3 norepinephrine
AHA2010)
ۿ: Cardiovascular: Arrhythmias, bradycardia, peripheral (digital) ischemia(uptodate 19.3 norepinephrine)
Ÿ : CO (, HR״) /븣 : , CO ణ (HR ״)
dz 뷮 b1 >> b2<->a1
: CO SVR , ҿ ȿ
, 뷮 a1>b1,b2 SVR CO(uptodate)
anaphylacis , septic shock 2(uptodate)
NTG (ȿ ſ ӽð ª)(ȯ ġ)
뷮 < 40ug/min : Ȯȿ : ɹⷮ ָ鼭 游(߽ƾ, PCWP) ҽŴ(ȯ ġ)
߰뷮 40~200ug/min : ư ȥ Ȯȿ :
Ȯ(SVR) ɹⷮ ϱ (ȯ ġ)
뷮 > 200ug/min : Ȯȿ 켼 : ⼭ʹ (ȯ ġ)
1. Ʈα۸
2. Ʈõ : Ȯȿ Ʈα۸
ϴ. Ȯȿ Ʈα۸ ϴ ,
ﰢ̰ ȿӽð ª(ȯ ġ)
50mg 5%DW 500 mixϿ
(ȯ ġ)
3) 뷮 : 0.5-10 mcg/kg/.( 1mcg/kg/ شٸ
, 3000mcg/hr= 3mg/hr ,50mg 500cc ͽϸ 1mg=10cc 30cc/hr=30mds)(ǰ)
߾Ⱦ (¾)
ҿ : Pure A agonist : ȿ . SVR Ѵ.
neurologic disorder, anathesia
induced hypotension , hyperdynamic sepsis . ƴϴ. SVR1200 (uptodate)
Ephedrine dz potency
, 븣dz к ڱϸ鼭 ȿ Ÿ post anesthesia induced hypotension (uptodate)
Isoproterenol(Isuprel) b1(ino,
chrono) HR , b2 ۿ ؼ MAP
ϰ, bradycardia
induced hypotension (uptodate)
? ̹ ؼ vasodilation
, bradycardia
ִ ִ()
Vasopressin (diabetes inspidus , variceal bleeding ) adrenergic
mechanism ƴϰ vasoconstriction , inotrophy Ѵ(uptodate)
refractory septic shock(2nd agent),
refractory anaphylacsis(uptodate)
PDE inhibitor
milrinone , inamrinone : inotropic, vasodilatory
action Ÿΰ , dysrhythmia . medically refractive heart failure δ, hypotension . (uptodate)
------------------------------------------------------------------------------------------------------------------------------------
sepsis hypotension , fluidְ Ĺ
Ҵµ, tachycardia ڴٷ ش. ڴٷ 2 ϵ ִ° 絥
ü ִ.
PSVT
: ڸ PO ֱѴ
Tachycardia
control : Ƹٷ, ڸ
Ⱓ ȯڵ鿡 ϴ
IV Ĺ
ī(denopamine : selective b-1 agonist) : Դ Ĺ(Ÿ ´µ)̶ ϸ ȴ. , ɺ ϶ . (R3)
Ÿ ۿ ϴ. Ÿ IVۿ , ̰ PO̴. ɹڼ п ġ ʴ 汸 (۸), congestive heart failure , pulmonary edema δ(wikipedia)
ᱹ ɺ ƴ ȯڴ IV Ĺ ۿ . (R3 ƴѵ)
ɺȯ
ī, , lasix , b-blocker(Ⱓ ) : װ (R3)
ACEI(Űǵ)
ۿ :
,
capacityø , cardiac output, stroke work, and volume
Ŵ(venous return
پ ϱ? ) (Űǵ)
, natriuresis
(excretion of sodium in the urine). (Űǵ)
Renin. Angiotensin Angiotensin
II and Aldosterone . Bradykinin . (Űǵ)
ñƮ(nicorandil)
BP , Ҽ
ִ(Ӹ blood flow) (峻)